A triterpenoid saponin that is cycloastragenol glycosylated at positions 3 and 6 by 2,3-di-O-acetyl-β-D-xylosyl and β-D-glucosyl residues respectively.
InChI=1S/C45H72O16/c1-21(47)56-33-24(50)19-55-38(34(33)57-22(2)48)60-28-11-13-45-20-44(45)15-14-41(7)35(43(9)12-10-29(61-43)40(5,6)54)23(49)17-42(41,8)27(44)16-25(36(45)39(28,3)4)58-37-32(53)31(52)30(51)26(18-46)59-37/h23-38,46,49-54H,10-20H2,1-9H3/t23-,24+,25-,26+,27-,28-,29-,30+,31-,32+,33-,34+,35-,36-,37+,38-,41+,42-,43+,44-,45+/m0/s1
AstragalosideΙ(As-Ι), one of the main active ingredients in Astragalus membranaceus, As-I stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway, thus highlighting the As-Ιfor pharmaceutical and medicinal applications such as treating bone disease. [1]
AstragalosideΙmay protect the cerebral tissue against the free radical damage in ischemia. [2]
AstragalosideΙcan inhibit the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway, therefore, reduces the nuclear translocation of phosphorylated NF-κB, leading to the down-regulation of the gene expressions of TNF-α, i NOS and IL-1β and thus lessened the production of iNOS, TNF-α and COX-2 protein. [3]
English website: Astragaloside I
Japanese website: Astragaloside I
Chinese website: Astragaloside I
[1] Xun Cheng †, Biaofang Wei †, Sun L, et al. Phytother Res, 2016,7.
[2] Luo Y M. Chinese Journal of Clinical Neurosciences, 1998(03):146-8.
[3] Liu H S, Wen-Hui L I, Shen H, et al. China Journal of Traditional Chinese Medicine & Pharmacy, 2016(05).
[4] Qin J P, Yao Y, Yun L I, et al. Chinese Traditional Patent Medicine, 2008, 30(10):1468-71.
